On June 5, 2026, the U.S. Food and Drug Administration cleared the Radius VSM and Accessories, a wearable vital-signs monitor from Masimo Corporation of Irvine, California, under 510(k) premarket notification number K254209. The device is classified as a Class II cardiovascular monitor under product code MHX, and the clearance followed the Traditional 510(k) pathway after the agency determined the device was substantially equivalent to a legally marketed predicate. For a company whose name most consumers learned only through a courtroom fight with Apple, the clearance is a reminder of where Masimo actually lives: at the unglamorous, high-stakes intersection of sensors, skin, and continuous data.
The Radius VSM is, in plain terms, a body-worn monitor designed to track a patient's vital signs continuously rather than at the periodic intervals of a nurse's rounds or a clinic visit. Where a traditional bedside monitor tethers a patient to a wall, a wearable vital-signs monitor untethers that measurement, letting the data follow the person as they move through a ward, a recovery floor, or eventually their own home. That mobility is the entire point. The clinical value of continuous monitoring is not just more data; it is the ability to catch the slow deterioration that intermittent checks miss — the gradual drift in heart rate or respiration that precedes a serious event.
Who made it, and why that matters
Masimo is not a household consumer brand, but it is one of the most consequential sensor companies in the world. It built its reputation on pulse oximetry — the measurement of blood-oxygen saturation — and specifically on signal-processing technology that holds up when a patient is moving or poorly perfused, the conditions under which older oximeters fail. That core competency is why the company's name surfaced in consumer-tech headlines: Masimo accused Apple of infringing its pulse-oximetry patents in the Apple Watch, and in late 2023 it won a U.S. International Trade Commission import ban that forced Apple to disable the blood-oxygen feature on the Series 9 and Ultra 2 in the United States. The dispute is the clearest illustration in recent memory that the sensing layer of a wearable is contested, valuable, and owned.
The Radius VSM clearance shows the other side of that story. While Apple's blood-oxygen feature is a wellness add-on inside a general-purpose smartwatch, Masimo's products are regulated medical devices that must clear the FDA before they reach a patient. The K254209 record is the paperwork that distinguishes the two worlds. A consumer wearable can ship a heart-rate graph as a lifestyle feature with no premarket review; a vital-signs monitor that a clinician will act on requires a substantial-equivalence determination, a product code, and an advisory-committee assignment — here, the cardiovascular panel.
What FDA clearance actually means here
It is worth being precise about what a 510(k) clearance is and is not. Clearance is not approval, and it is not a finding that the device is safe and effective in the absolute sense that the word "approval" implies for high-risk products. A 510(k) is a determination that the new device is substantially equivalent to a predicate device already on the market — that it has the same intended use and the same or comparably safe technological characteristics. The decision code on the Radius VSM record, SESE, signals exactly that: substantially equivalent. The clearance type listed is Traditional, the standard, full-length pathway, as opposed to the Special or Abbreviated routes used for modifications and standards-based submissions.
For a reader trying to understand the consumer-health hardware market, that distinction is the whole game. The 510(k) system is the regulatory backbone of the entire wearable-medical category. It is how a body-worn monitor, a continuous glucose system, or an ECG patch reaches the U.S. market without the multi-year clinical trials a novel drug or implant demands. It rewards iteration on proven ground — each new device leaning on a predicate — which is why the category moves fast and why so much innovation is incremental refinement of sensing accuracy rather than wholesale reinvention.
The consumer-tech angle
The Radius VSM sits on the boundary that defines the next decade of consumer health hardware. On one side are lifestyle wearables — smartwatches and rings that estimate heart rate, sleep, and oxygen and disclaim, in fine print, that they are not medical devices. On the other side are regulated monitors like the Radius VSM, cleared for clinical use, built by a company whose patents the largest consumer-electronics firm in the world was found to infringe. The two are converging. Hospitals want the comfort and mobility of a wearable; consumers increasingly want the rigor of a cleared device. The companies that own the sensing IP and can clear the regulatory bar — Masimo foremost among them — are positioned to supply both.
The K254209 clearance does not, on its own, put a Masimo monitor on a consumer's wrist at retail. But it deepens a portfolio that already forced the world's most valuable consumer-hardware company to surgically remove a feature from its flagship product. Following the docket, rather than the keynote, is how you see that. The Apple Watch grabbed the blood-oxygen headlines; the FDA's 510(k) database is where the company that owns the underlying measurement quietly keeps clearing the next device. The Radius VSM is one more entry in that ledger, and the ledger is the story.
For anyone watching consumer health hardware, the takeaway is structural. The form factor that matters — untethered, continuous, body-worn — is the same whether the badge says Apple or Masimo. What separates a regulated monitor from a lifestyle gadget is precisely the record we just read: a product code, an advisory committee, a substantial-equivalence finding, and a K-number. That paperwork is not a footnote to the product. It is the moat.